Clinical Trial Update: 68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 68Ga-DOTA-Bombesin PET/MRI for imaging prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 68Ga-DOTA-Bombesin (DOTA-Bombesin radiopharmaceutical labeled with Gallium-68)

Snippet

Sponsor: Stanford University | Conditions: Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11